Finland· FI-REL-REL52489
Esperoct
A coagulation factor viii product containing turoctocog alfa pegol, registered in Finland by Novo Nordisk A/S. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor viii is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Coagulation factor viii · ATC B02BD02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Turoctocog alfa pegol
- Manufacturer
- Novo Nordisk A/S
- Country
- Finland (FI)
- ATC code
- B02BD02
- ATC class
- Coagulation factor VIII
- Defined daily dose
- 1 TSD, E
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for coagulation factor viii.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor viii · interactions on record
4 records
- 2 severe
- 2 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- EmicizumabB02BX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor viii in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandEsperoct 500 IU Powder and solvent for solution for injectionNovo Nordisk A/S
- SwedenEsperoct 1000 IE Pulver och vätska till injektionsvätska, lösningNovo Nordisk A/S
- SwitzerlandEsperoct
- CzechiaESPEROCTNovo Nordisk A/S, Bagsvaerd
- IcelandEsperoctNovo Nordisk A/S*
- NetherlandsEsperoct 1000 IE, poeder en oplosmiddel voor oplossing voor injectieNovo Nordisk A.S.
- PolandEsperoctNovo Nordisk A/S
- BelgiumEsperoct 1000 IUNovo Nordisk
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Esperoct
- Norway · Esperoct
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5c1c0d4b-94c4-4464-8454-bcdb0d6c61d2 GET /v1/drugs/5c1c0d4b-94c4-4464-8454-bcdb0d6c61d2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektiokuiva-aine ja liuotin, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "500 IU",
"atc_label": "hyytymistekijä VIII",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/19/1374/001",
"fimea_rel_id": "REL52489",
"authorised_at": "2019-06-20"
}See everything about coagulation factor viii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.